中枢神经系统及局限性隐球菌病患者中的中和性抗粒细胞-巨噬细胞集落刺激因子自身抗体:纵向随访与文献综述
前瞻性纳入23例无HIV感染的播散性或少见隐球菌病患者,6例抗GM-CSF自身抗体阳性。阳性患者真菌培养均为隐球菌格特变种VGII,部分仅肺部或骨骼肌肉受累;中枢感染者抗体浓度更高,血清CrAg初始及峰值更高、抗原血症持续时间更长。完成抗真菌治疗者均预后良好无复发。
要点
- 对播散性或不明原因局限性隐球菌病患者可考虑检测抗GM-CSF自身抗体。
- 抗GM-CSF抗体阳性者培养阳性均为隐球菌格特变种VGII。
- 完成抗真菌治疗后复发罕见,尽管自身抗体持续存在。
核心结论
- 对既往健康且患播散性隐球菌病以及不明原因局限性隐球菌病的患者,均应考虑检测抗GM-CSF自身抗体。
- 尽管抗GM-CSF自身抗体持续存在,完成抗真菌治疗后的复发罕见。
研究设计与样本
- 前瞻性纳入无人类免疫缺陷病毒感染的成人播散性或少见隐球菌病患者,比较抗GM-CSF自身抗体阳性(病例组)与阴性(对照组)患者的人口学、临床特征、血清隐球菌抗原滴度动力学、抗GM-CSF自身抗体浓度及治疗结局,并复习文献。
- 共纳入23例患者,其中6例抗GM-CSF自身抗体阳性。
主要发现
- 所有真菌培养阳性的病例组患者(5/5,100%)均感染隐球菌格特变种VGII。
- 病例组中3例仅肺部受累,1例仅有骨骼肌肉病灶。
- 中枢神经系统隐球菌病患者血清抗GM-CSF自身抗体浓度高于神经外隐球菌病患者。
- 病例组初始及峰值血清隐球菌抗原水平高于对照组,抗原血症持续时间长于对照组。
- 所有完成抗真菌治疗的病例组患者均预后良好,无复发。
临床怎么用
- 作者认为,对既往健康且患播散性隐球菌病以及不明原因局限性隐球菌病的患者,均应考虑检测抗GM-CSF自身抗体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neutralizing anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies (AAbs) have been increasingly recognized to predispose healthy individuals to disseminated cryptococcosis. However, studies have only considered patients with central nervous system (CNS) infection. No longitudinal study has captured the disease spectrum and clinical course. METHODS: We prospectively enrolled adults without human immunodeficiency virus infection who had disseminated or unusual cryptococcosis. We compared the demographics, clinical features, kinetics of serum cryptococcal antigen (CrAg) titers, anti-GM-CSF AAb concentrations, and treatment outcomes between patients with (case patients) and without (control patients) anti-GM-CSF AAbs. Additional reports from the literature were also reviewed. RESULTS: Twenty-three patients were enrolled, of whom 6 tested positive for anti-GM-CSF AAbs. All case patients with positive fungal cultures (5/5 [100%]) were infected with Cryptococcus gattii VGII. Among them, 3 had exclusively pulmonary involvement, and 1 had only musculoskeletal lesions. Patients with CNS cryptococcosis exhibited a higher serum concentration of anti-GM-CSF AAbs than those with extraneural cryptococcosis. Case patients had higher initial and peak levels of serum CrAg and longer duration of antigenemia compared with the control patients. All case patients who had completed antifungal therapy had favorable outcomes without recurrence. CONCLUSIONS: Testing for anti-GM-CSF AAbs should be considered for not only previously healthy patients with disseminated cryptococcosis but also those with unexplained, localized cryptococcosis. Recurrence after completion of antifungal therapy was rare despite the persistence of anti-GM-CSF AAbs.
引用
- Kuo PH, Wu UI, Pan YH, et al. Neutralizing Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Patients With Central Nervous System and Localized Cryptococcosis: Longitudinal Follow-up and Literature Review. Clin Infect Dis. 2022. PMID: 34718451. doi:10.1093/cid/ciab920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。